A revision of hepatitis C treatment;Hepatite C: Tratamento revisitado

Arquivos de Gastroenterologia

Volumn 41, Issue 1, 2004, Pages 1-2

  Siciliano, Rinaldo Focaccia ^a   Boulos, Marcos ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chronic hepatitis C; Interferons; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

CLINICAL RESEARCH; DRUG CHOICE; DRUG EFFICACY; EDITORIAL; HEPATITIS C; HUMAN; IMMUNOTHERAPY; MEDICAL LITERATURE;

EID: 4043132981     PISSN: 00042803     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-28032004000100001     Document Type: Editorial

References (14)

1. Acras RN. Pedroso MLA, Caum LC, Pisani JC, Amarante HMBS, Carmes ER. A taxa de resposta sustentada da hepatite C crô3nica ao tratamento com os diversos interferons alfa e ribavirinas distribuídos pelo governo brasileiro é semelhante à da literatura mundial. Arq Gastroenterol 2004;41(1):3-9.
2. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A non-B hepatitis genome. Science 1989;224,359-62.
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marines G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Huffman J, Yu J. Peguinterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
4. Gonçales Jr F, Vigani A, Gonsales N. Peginterferon alpha-2b (PEG-INF) plus ribavirin (RBV) in Brazilian patients with chronic hepatitis C: 12 week viral clereance [abstract], Hepatology 2002;36:588A.
5. Heathcote EJ, Shiftman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Huffman J, De Pamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80.
6. Herrine SK, Brown R, Esposito S. Efficacy and safety of peginterferon Alpha-23 (Pegasys) combination therapies in patients with chronic hepatitis C (CHC) who relapsed on interferon alpha-2a plus ribavirin (Rebeton) therapy. Boston, Mass.: AASLD; 2002.
7. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A prelimimary report. N Engl J Med 1986;315:1575-8.
8. Kjaergard LL, Krogsaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BJM 2001;323:1151-5.
9. Lindsay KL, Trepo C, Heintges T, Shiftman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
10. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
11. Simon DM, Gordon SC, Kaplan MM, Koff RS, Regenstein F, Everson G, Lee YM, Weiner F, Silverman A, Plasse T, Fedorczyk D, Liao MJ. Treatment of chronic hepatitis C with interferon alfa-n3: a multicenter, randomized, open-label trial. (See comment in: Hepatology 1997;26:1366-7). Hepatology 1997;25:445-48.
12. Simon DM, Gordon SC, Kaplan MM, Koff RS, Regenstein F, Everson G, Lee YM, Weiner F, Silverman A, Plasse T, Fedorczyk D, Liao MJ. Treatment of chronic hepatitis C with interferon alfa-n3: a multicenter, randomized, open-label trial. (See comment in: Hepatology 1997;26:1366-7). Hepatology 1997;25:445-48.
13. Tong MJ, Blatt LM, McHutchinson JG, Co RL, Conrad A. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997:26:1640-5.
14. Zeuzem S, Feinman S, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Huffman J, Brunda MJ. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.